Conclusion
Taken together, the findings of the current study present evidence suggesting that SGO1 could inhibit the growth and invasion of PCa cells, highlighting its potential as a novel therapeutic target for the treatment of PCa.
Methods
Quantitative real-time PCR (qRT-PCR) was used to determine the expression of SGO1 in PCa tissues and cell lines. The correlation between SGO1 expression and clinicopathological characteristics of PCa patients was analyzed using Kaplan-Meier analysis. SGO1 siRNA was successfully constructed and transfected into PCa cell lines (LNCaP and PC3). The knockdown efficacy was assessed by qRT-PCR. MTT assay and Transwell assay were conducted to observe the effect of SGO1 on the proliferation and invasion of PCa cell lines.
Objective
The aim of the study was to investigate the role of shugoshinl (SGO1) in human prostate cancer (PCa). Materials and
Results
SGO1-expression levels were found to be higher in the PCa tissues and cell lines. Correlation was identified between the expression of SGO1 and preoperative prostate-specific antigen (P=0.017), lymph-node metastasis (P=0.044), and Gleason score (P=0.041). Patients with higher SGO1 expression displayed more advanced clinicopathological characteristics in addition to a shorter biochemical recurrence-free survival time. Additionally, SGO1 knockdown resulted in the inhibition of PCa cell proliferation, migration, and invasion.